Haematologisch Onkologische Praxis Eppendorf

At Haematologisch Onkologische Praxis Eppendorf in Hamburg, clinical research is strongly focused on gastrointestinal cancers and other solid tumors. Many studies are designed to test new treatment combinations, improve survival outcomes, and refine care for patients with advanced or resectable disease.

• Gastric cancer and gastroesophageal junction adenocarcinoma are major research priorities, with trials exploring new targeted and immunotherapy-based approaches.
• Colorectal cancer studies include advanced, metastatic, and biomarker-defined disease, often aiming to improve treatment effectiveness and disease control.
• Esophageal cancer and esophagogastric adenocarcinoma trials are evaluating better options for both locally advanced and metastatic settings.

Overall, the site is active in assessing whether newer combinations of immunotherapy, targeted therapy, and chemotherapy can improve outcomes across a wide range of cancers.

This research area centers on gastric, gastroesophageal junction, and esophageal cancers, including both localized and advanced disease. The trials are mainly intended to evaluate new treatment strategies that may strengthen tumor control and support better long-term outcomes.

• Gastric adenocarcinoma studies are examining novel combinations for first-line and perioperative treatment.
• HER2-positive and FGFR2b-expressing tumors are being investigated to better match treatment to tumor biology.
• Esophageal squamous cell carcinoma and esophagogastric adenocarcinoma trials are focused on improving response and survival.

The research includes efforts to test new antibodies, antibody-drug conjugates, and checkpoint inhibitors in ways that may offer more effective treatment choices for patients with difficult-to-treat upper digestive tract cancers.

The site also conducts extensive research in colorectal cancer, including metastatic colorectal cancer, rectal cancer, and colon cancer. These trials aim to improve survival, reduce recurrence, and identify better treatment options for patients with biomarker-defined disease.

• Metastatic colorectal cancer is a central focus, with trials assessing new combinations for later-line and first-line treatment.
• Rectal cancer and colon cancer studies include approaches for locally advanced and resectable disease.
• Molecular subtypes such as BRAF V600E, KRAS G12C, MSI-H/dMMR, and MSS/pMMR are being used to guide research.

These studies are designed to evaluate treatment effectiveness, support personalized medicine, and clarify whether newer targeted or immune-based strategies can improve outcomes compared with standard care.

Another important area at this site is breast cancer, especially hormone receptor-positive, HER2-negative, and advanced or metastatic disease. The trials are mainly testing whether newer therapies can extend disease control and provide better options after prior treatment.

• Advanced breast cancer studies focus on improving outcomes in patients whose disease has progressed.
• HR-positive and HER2-negative disease is being studied with targeted endocrine-based combinations.
• Biomarker-guided treatment research includes tumors with ESR1 or PIK3CA/AKT1/PTEN alterations.

In addition, the site is involved in broader precision oncology research, helping determine how tumor markers can be used to select more effective therapies across different cancer types.

Beyond the main disease groups, the Studienzentrum in Hamburg is active in studies on pancreatic cancer, biliary tract cancer, and other advanced solid tumors. These trials often aim to expand treatment choices where standard options remain limited.

• Pancreatic ductal adenocarcinoma research is evaluating new combinations to improve overall survival.
• Biliary tract cancer studies are examining whether novel regimens can produce better response rates.
• Advanced solid tumors with specific mutations, including KRAS p.G12C, are being studied to support mutation-targeted treatment development.

Across these programs, the site is contributing to research that seeks safer, more effective therapies and better ways to treat patients with aggressive cancers of the digestive system and beyond.